These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 20063132)
1. Rituximab therapy for refractory immune thrombocytopenic purpura in elder patients. Hangaishi A; Takahashi T; Masuda A; Okada S; Kandabashi K; Kurokawa M Int J Hematol; 2010 Mar; 91(2):336-7. PubMed ID: 20063132 [No Abstract] [Full Text] [Related]
2. Slow responses to standard dose rituximab in immune thrombocytopenic purpura. Kelly K; Gleeson M; Murphy PT Haematologica; 2009 Mar; 94(3):443-4; author reply 444-5. PubMed ID: 19252177 [No Abstract] [Full Text] [Related]
3. Successful treatment with rituximab of refractory idiopathic thrombocytopenic purpura in a patient with Kabuki syndrome. Torii Y; Yagasaki H; Tanaka H; Mizuno S; Nishio N; Muramatsu H; Hama A; Takahashi Y; Kojima S Int J Hematol; 2009 Sep; 90(2):174-176. PubMed ID: 19662467 [TBL] [Abstract][Full Text] [Related]
4. Combination of romiplostim and rituximab: effective therapy of severe immune thrombocytopenia. Pohlen M; Sargin B; Zicholl S; Bisping G; Müller-Tidow C; Berdel WE; Mesters R; Koschmieder S Eur J Haematol; 2010 Apr; 84(4):362-4. PubMed ID: 20050881 [No Abstract] [Full Text] [Related]
5. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Zaja F; Battista ML; Pirrotta MT; Palmieri S; Montagna M; Vianelli N; Marin L; Cavallin M; Bocchia M; Defina M; Ippoliti M; Ferrara F; Patriarca F; Avanzini MA; Regazzi M; Baccarani M; Isola M; Soldano F; Fanin R Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395 [TBL] [Abstract][Full Text] [Related]
6. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261 [TBL] [Abstract][Full Text] [Related]
7. [Good response to treatment with rituximab in a child with refractory idiopathic thrombocytopenic purpura]. Fríguls-Francitorra B; Almazán-Castro F; Manchón GJ Med Clin (Barc); 2006 Sep; 127(12):478-9. PubMed ID: 17040639 [No Abstract] [Full Text] [Related]
8. The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab. Kuwana M; Iki S; Urabe A Am J Hematol; 2007 Sep; 82(9):846-8. PubMed ID: 17506067 [TBL] [Abstract][Full Text] [Related]
9. Treatment of an infant with severe acute refractory immune thrombocytopenic purpura using combination therapy including rituximab. Iesato K; Hatakeyama N; Yamamoto M; Hori T; Inazawa N; Tsutsumi H; Suzuki N Pediatr Blood Cancer; 2009 Aug; 53(2):203-5. PubMed ID: 19301247 [TBL] [Abstract][Full Text] [Related]
10. [Use of rituximab in resistant thrombocytopenic purpura]. Zambrano-Velarde MA; de la O-Peña D; Chávez-Peña Q; Bedolla-Barajas M Rev Med Inst Mex Seguro Soc; 2012; 50(2):203-8. PubMed ID: 22882991 [TBL] [Abstract][Full Text] [Related]
11. Use of rituximab in refractory autoimmune thrombocytopenia following an autologous stem cell transplant. Price S; Cumpston A; Altaha R Hematology; 2006 Feb; 11(1):43-4. PubMed ID: 16522548 [TBL] [Abstract][Full Text] [Related]
12. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Schweizer C; Reu FJ; Ho AD; Hensel M Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529 [TBL] [Abstract][Full Text] [Related]